Health & Environmental Research Online (HERO)


Print Feedback Export to File
8431694 
Journal Article 
Carmustine (BCNU) in the treatment of malignant tumors (Rumanian) 
Gherman Gr.; Mirza, V; Lazarov, P 
1974 
Oncologia
ISSN: 1390-0110 
13 
421-428 
Romanian; Moldavian; Moldovan 
A treatment with BCNU (1,3 bis(2 chlorethyl) 1 nitrosourea) was applied in 89 patients suffering from Hodgkin's disease (19 cases), reticulolymphosarcoma (28 cases), bronchopulmonary carcinoma (30 cases), other solid tumors (12 cases). BCNU was administered by the oral route in enterosoluble capsules containing 25 mg. The total dose administered was 300 mg/m2. Patients received 2-9 such doses at intervals of 6-8 weeks. The treatment was efficient in 68.42% of the patients with Hodgkin's disease (13/19), in 39.28% of the reticulosarcomas (11/28), in 33.33% of the bronchopulmonary carcinomas (10/30) and in 16.66% of the other solid tumors (2/12). Two categories of side effects were observed: digestive (nausea and vomiting) in 42.69% of the patients and hematologic (leuko and thrombocytopenia with a late onset) in 12.35% of the cases.